Back to search
Hyperbilirubinemia, Neonatal
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hyperbilirubinemia, Neonatal trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hyperbilirubinemia, Neonatal trials you may qualify forThis is a prospective, open-label, randomized controlled trial conducted at Lattakia University Hospital (Tishreen University), aiming to evaluate the efficacy…
Neonatal jaundice, or neonatal hyperbilirubinemia, is a common medical issue in the first two weeks of life, causing prolonged hospitalization and readmissions.…
The goal of this clinical trial is to learn if modified diagnosis and treatment (MDT) of neonatal hemolysis (a common cause to newborn jaundice) incorporated wi…
The objective of this study is to ascertain the diagnostic threshold of end-tidal carbon monoxide (ETCOc, adjusted for ambient CO levels) within the first three…
About 50% of full-term newborns and 80% of premature infants develop jaundice which is due to hyperbilirubinemia. In the majority of cases, jaundice disappears…
About 60% of babies born after 36 weeks of pregnancy have jaundice during the first two weeks of life. Due to the accumulation of bilirubin in the bloodstream,…
Bilisensors are devices designed to measure the cumulative dose of phototherapy administered to neonates undergoing treatment for hyperbilirubinemia. The curren…
This study aims to examine the effect of white cover and massage application on bilirubin levels and phototherapy duration in newborns with ABO incompatibility…
The timing of umbilical cord clamping has been widely discussed in the scientific community. As part of the worldwide strategies to reduce childhood iron defic…